Table 1.
Schedule of enrolment, treatments, and assessments.
| Study period | Screening | Baseline | Treatment period | Treatment period | Treatment period | Follow-up period |
|---|---|---|---|---|---|---|
| week 0 | Week 2 | Week 4 | Week 6 | Week 14 | ||
| Eligibility screening | ○ | |||||
| Demographic data | ○ | |||||
| Case data | ○ | |||||
| Inclusion criteria | ○ | |||||
| Exclusion criteria | ○ | |||||
| Informed consent | ○ | |||||
| Treatment | ○ | ○ | ○ | |||
| Outcome assessment | ||||||
| (1) QST | ○ | ○ | ○ | ○ | ○ | |
| (2) ZBPI | ○ | ○ | ○ | ○ | ○ | |
| (3) Dosage of analgetic | ○ | ○ | ○ | ○ | ○ | |
| (4) SF-36 | ○ | ○ | ○ | ○ | ○ | |
| (5) HADS | ○ | ○ | ○ | ○ | ○ | |
| (6) PSQI | ○ | ○ | ○ | ○ | ○ | |
| Safety assessment | ○ | ○ | ○ | ○ | ||
| Recurrence of PHN | ○ | |||||
○, required; HADS, Hospital Anxiety and Depression Scale; PHN, postherpetic neuralgia; PSQI, Pittsburgh Sleep Quality Index; QST, Quantitative Sensory Testing; SF-36, Short Form 36 Health Survey; ZBPI, Zoster Brief Pain Inventory.